May 30 -
A federal judge on Friday rejected Mallinckrodt Plc’s request to reconsider or put on hold a ruling that allowed the U.S. government to force the drugmaker to pay higher rebates to state Medicaid programs after it dramatically hiked the price of its top-selling drug.
U.S. District Judge Thomas Hogan in Washington, D.C., declined to reconsider an earlier ruling from March that will force Mallinckrodt to pay $650 million to cover retroactive rebates for the drug, H.P. Acthar Gel.
To read the full story on Westlaw Practitioner Insights, click here: bit.ly/3eAd0Hc
Our Standards: The Thomson Reuters Trust Principles.